A large-scale genome-wide association study published in Nature in April 2026, conducted by 23andMe researchers using data from 27,885 GLP-1 medication users, identified a specific variant in the GLP1R gene the gene that encodes the primary receptor these drugs target associated with differential weight loss efficacy
Beyond convenience, this transition also aims to improve health outcomes
Manufactured to GMP Standards: Ensuring full compliance with Good Manufacturing Practices (GMP) and stringent quality control processes
However, this is controversial, and more evidence is needed
These medicines include semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1 agonist